Avalon Trust Co Decreases Stake in iShares Biotechnology ETF $IBB

Avalon Trust Co reduced its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 4.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,015 shares of the financial services provider’s stock after selling 5,030 shares during the period. iShares Biotechnology ETF makes up 1.1% of Avalon Trust Co’s portfolio, making the stock its 22nd largest holding. Avalon Trust Co owned approximately 0.30% of iShares Biotechnology ETF worth $15,436,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in IBB. Citigroup Inc. raised its stake in iShares Biotechnology ETF by 88.5% in the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock worth $410,322,000 after buying an additional 1,505,976 shares in the last quarter. Millennium Management LLC lifted its stake in shares of iShares Biotechnology ETF by 140.8% in the 1st quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock valued at $5,330,000 after purchasing an additional 143,893 shares during the period. Jones Financial Companies Lllp increased its stake in shares of iShares Biotechnology ETF by 763.3% in the 1st quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock valued at $19,347,000 after purchasing an additional 133,744 shares in the last quarter. Ashton Thomas Private Wealth LLC increased its holdings in iShares Biotechnology ETF by 769.9% in the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 63,691 shares of the financial services provider’s stock worth $8,058,000 after acquiring an additional 56,369 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. increased its stake in iShares Biotechnology ETF by 35.0% during the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 116,115 shares of the financial services provider’s stock worth $14,690,000 after buying an additional 30,115 shares in the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Trading Up 0.5%

Shares of NASDAQ IBB opened at $164.96 on Thursday. iShares Biotechnology ETF has a 52 week low of $107.43 and a 52 week high of $165.81. The firm has a 50-day simple moving average of $150.12 and a 200-day simple moving average of $136.49.

iShares Biotechnology ETF Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were given a $0.0828 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 dividend on an annualized basis and a yield of 0.2%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.